United Kingdom Pemetrexed Market Size & Outlook, 2025-2033


United Kingdom Pemetrexed Market Insights

  • Reed Intelligence analysis indicates that the United Kingdom Pemetrexed Market size, valued at USD 145.36 Million in 2024, is expected to expand to USD 172.76 Million by 2033.
  • The United Kingdom market is forecasted to expand at a CAGR of 1.97% spanning 2026–2033.
  • Malignant Pleural Mesothelioma held the leading position among By Application segments in 2024, based on market size.
  • Non-Squamous NSCLC is projected to post the fastest growth rate, sustaining its position as the most attractive By Application segment during the forecast horizon.

Other Key Findings


  • As of 2024, United Kingdom held 6.21% of the global Pemetrexed Market size.
  • By 2033, United States is anticipated to capture the largest share of the global Pemetrexed Market.
  • In Europe, Germany is expected to lead the regional Pemetrexed Market size by 2033.
  • Nordic will remain the fastest-growing market in Europe, reaching USD 39.9 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 145.36 Million
Market Size In 2033 USD 172.76 Million
Largest segment Malignant Pleural Mesothelioma
Units Revenue in USD Million
CAGR 1.97% (2025-2033)
Segmnetation Covered
By Application
  1. Malignant Pleural Mesothelioma
  2. Non-Squamous NSCLC
By End-User
  1. Hospitals
  2. Oncology Centers
  3. Online Pharmacies
  4. Offline Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends